CLEVER LEAVES HOLDINGS INC (CLVR) Fundamental Analysis & Valuation
NASDAQ:CLVR • CA1867602031
Current stock price
3 USD
+0.89 (+42.18%)
At close:
3.05 USD
+0.05 (+1.67%)
After Hours:
This CLVR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CLVR Profitability Analysis
1.1 Basic Checks
- CLVR had negative earnings in the past year.
- In the past year CLVR has reported a negative cash flow from operations.
- CLVR had negative earnings in each of the past 5 years.
- In the past 5 years CLVR always reported negative operating cash flow.
1.2 Ratios
- CLVR has a worse Return On Assets (-57.31%) than 62.56% of its industry peers.
- Looking at the Return On Equity, with a value of -73.94%, CLVR is in line with its industry, outperforming 47.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.31% | ||
| ROE | -73.94% | ||
| ROIC | N/A |
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of CLVR (37.63%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of CLVR has declined.
- The Profit Margin and Operating Margin are not available for CLVR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
2. CLVR Health Analysis
2.1 Basic Checks
- CLVR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for CLVR has been increased compared to 1 year ago.
- Compared to 1 year ago, CLVR has a worse debt to assets ratio.
2.2 Solvency
- CLVR has an Altman-Z score of -9.24. This is a bad value and indicates that CLVR is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -9.24, CLVR is not doing good in the industry: 76.41% of the companies in the same industry are doing better.
- CLVR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
- CLVR's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. CLVR outperforms 51.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.24 |
ROIC/WACCN/A
WACC10.07%
2.3 Liquidity
- A Current Ratio of 2.40 indicates that CLVR has no problem at all paying its short term obligations.
- CLVR has a worse Current ratio (2.40) than 60.00% of its industry peers.
- CLVR has a Quick Ratio of 1.63. This is a normal value and indicates that CLVR is financially healthy and should not expect problems in meeting its short term obligations.
- CLVR has a worse Quick ratio (1.63) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.4 | ||
| Quick Ratio | 1.63 |
3. CLVR Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 78.15% over the past year.
- CLVR shows a small growth in Revenue. In the last year, the Revenue has grown by 4.80%.
- CLVR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.85% yearly.
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- The Revenue is expected to grow by 128.91% on average over the next years. This is a very strong growth
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. CLVR Valuation Analysis
4.1 Price/Earnings Ratio
- CLVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CLVR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. CLVR Dividend Analysis
5.1 Amount
- No dividends for CLVR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLVR Fundamentals: All Metrics, Ratios and Statistics
3
+0.89 (+42.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-23 2024-05-23/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners2.55%
Inst Owner Change-22.23%
Ins Owners342.65%
Ins Owner Change0%
Market Cap5.25M
Revenue(TTM)17.42M
Net Income(TTM)-17.91M
Analysts43.33
Price Target24.48 (716%)
Short Float %0.5%
Short Ratio0.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.79%
Min Revenue beat(2)-27.98%
Max Revenue beat(2)-21.6%
Revenue beat(4)1
Avg Revenue beat(4)-10.9%
Min Revenue beat(4)-27.98%
Max Revenue beat(4)8.33%
Revenue beat(8)3
Avg Revenue beat(8)-12.3%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.22 | ||
| P/tB | 0.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-11.4
EYN/A
EPS(NY)-6.73
Fwd EYN/A
FCF(TTM)-6.59
FCFYN/A
OCF(TTM)-6.58
OCFYN/A
SpS9.95
BVpS13.84
TBVpS12.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.31% | ||
| ROE | -73.94% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.63% | ||
| FCFM | N/A |
ROA(3y)-74.55%
ROA(5y)-49.14%
ROE(3y)-100.17%
ROE(5y)-67.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.93%
GM growth 5YN/A
F-Score3
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.31% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.4 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z | -9.24 |
F-Score3
WACC10.07%
ROIC/WACCN/A
Cap/Depr(3y)81.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)18.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.01%
EPS Next Y29.03%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.8%
Revenue growth 3Y12.85%
Revenue growth 5YN/A
Sales Q2Q%0.61%
Revenue Next Year50%
Revenue Next 2Y128.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.41%
OCF growth 3YN/A
OCF growth 5YN/A
CLEVER LEAVES HOLDINGS INC / CLVR Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CLEVER LEAVES HOLDINGS INC (CLVR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CLVR.
Can you provide the valuation status for CLEVER LEAVES HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to CLEVER LEAVES HOLDINGS INC (CLVR). This can be considered as Overvalued.
Can you provide the profitability details for CLEVER LEAVES HOLDINGS INC?
CLEVER LEAVES HOLDINGS INC (CLVR) has a profitability rating of 1 / 10.
What is the expected EPS growth for CLEVER LEAVES HOLDINGS INC (CLVR) stock?
The Earnings per Share (EPS) of CLEVER LEAVES HOLDINGS INC (CLVR) is expected to grow by 29.03% in the next year.